Table 3. Mean screening and baseline FVC (% predicted) of GALS-001 patients, separated by treatment type and site.

Time Point	Placebo All	Placebo Site 001	Placebo Site 002	GM604 All	GM604 Site 001	GM604 Site 002
Screening	87.30	70.50	104.00	90.40	89.80	91.00
Baseline	81.30	73.50	89.00	89.10	89.50	88.75